-

Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, August 11, 2020, at 8:30 a.m. ET to review its second quarter 2020 financial results and provide an update on the company.

The webcast will be available on the “Investors & Media” section of the Gamida Cell website at www.gamida-cell.com. To participate in the live call, please dial 1-866-930-5560 (domestic) or 1-409-216-0605 (international) and refer to conference ID number 8888903. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit https://www.gamida-cell.com.

Contacts

Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264

Matthew Corcoran (media)
mcorcoran@tenbridgecommunications.com
1-617-866-7350

Industry:

Gamida Cell Ltd.

NASDAQ:GMDA
Release Summary
Gamida Cell announced that it will report its second quarter 2020 financial results on Tuesday, August 11, 2020.
Release Versions
English
$Cashtags
$GMDA

Contacts

Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264

Matthew Corcoran (media)
mcorcoran@tenbridgecommunications.com
1-617-866-7350

More News From Gamida Cell Ltd.

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”). Pursuant to the loan agreement, Gamida Cell’s wholly-owned subsidiary, as borrower, will draw down $25 million from the faci...

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences: 34th Annual Piper Sandler Healthcare Conference, November 29, 2022 with a fireside chat at 1:00 p.m. ET. Evercore ISI Healthcare Conference, December 1, 2022 with a fireside chat at 2:15 p.m....

Gamida Cell Provides Regulatory Update on Omidubicel

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and Drug Administration (FDA) relating to the company’s Biologics License Application (BLA) for omidubicel, the company’s advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant. As part of its ongoing BLA revi...
Back to Newsroom